Global Prostate Cancer Disease Coverage Forecast and Market Analysis 2020-2036 – Xtandi will Remain the Best-selling Therapy Over the Next Decade -…
Posted: December 11, 2020 at 9:54 am
Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Prostate Cancer Disease Coverage Forecast and Market Analysis to 2036" report has been added to ResearchAndMarkets.com's offering.
Newly approved therapies for castration-resistant prostate cancer are set to create a shift in the way that the disease is treated, while creating a competitive environment for new market entrants.
Latest Key Takeaways
The report estimates that in 2018, there were 1.3 million incident cases of prostate cancer worldwide in males aged 40 years and older, and forecasts that number to increase to 1.5 million cases by 2027.
In the US, prostate cancer is the most common non-cutaneous malignancy diagnosed in men, and is the second-leading cause of cancer mortality in men behind lung cancer.
The overall likelihood of approval of a Phase I prostate cancer asset is 4.9%, and the average probability a drug advances from Phase III is 51.5%. Prostate cancer drugs, on average, take 9.0 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
Pfizer's next-generation androgen receptor (AR) inhibitor Xtandi is the market leader in prostate cancer due to its established efficacy across prostate cancer segmentations and a lack of near-term generic competition. Bolstered by recent and planned expansions into additional prostate cancer segments, Xtandi will continue to be the leading option in this indication. Future expansion opportunities include potential use in combination with PARP inhibitors Talzenna or Rubraca in metastatic castration-resistant prostate cancer (mCRPC) patients.
Xtandi is also being trialed in combination with leuprolide in the Phase III EMBARK study for non-metastatic hormone-sensitive prostate cancer patients progressing on definitive therapy. Potential expansion into this segment represents a significant opportunity to improve outcomes earlier in the treatment paradigm, but the combination will have to demonstrate a significant benefit over existing localized treatment options to justify the additional clinical and financial toxicity of Xtandi treatment.
Since the launch of generic abiraterone in the US in November 2018, sales of Johnson & Johnson's cytochrome P450c17 inhibitor Zytiga have begun to erode. Further generic erosion is expected in the EU and Japanese markets in the next few years, decimating sales of the multi-blockbuster. Although branded Zytiga will continue to decrease in market share, use of abiraterone as part of standard regimens will continue and may expand to include several novel combinations.
The PARP inhibitors Rubraca and Lynparza were both approved in the US in May 2020 for the treatment of mCRPC patients following AR inhibitor therapy. Rubraca received accelerated conditional approval in mCRPC with a deleterious BRCA mutation (germline and/or somatic), while Lynparza received full approval for use in the broader homologous recombination deficient (HRD) population. To potentially differentiate the PARP assets, both are being trialed in the first-line setting of mCRPC; Rubraca in combination with Xtandi against Xtandi alone, and Lynparza with abiraterone against abiraterone alone. There is potential synergy with these combinations as its hypothesized that AR inhibitors may sensitize tumors to PARP treatment by reducing DNA damage repair (DDR) expression.
Late-phase PARP inhibitors Zejula and Talzenna are also being developed in combination with next-generation treatments and will join a crowded PARP treatment space. Zejula is being tested in combination with abiraterone against abiraterone alone as first-line therapy for mCRPC patients. Similarly, Talzenna is being studied in combination with physician's choice of Xtandi or enzalutamide in mCRPC patients, also as a first-line option. The potential synergy of the PARP inhibitors with AR modulators is promising, but a strong benefit will have to be seen to justify use in the front-line setting of mCRPC. If approved, it is likely that these regimens will be limited to the HRD or even BRCA populations, where they will have strong utility but somewhat limited commercial impact due to the relatively small prevalence of these biomarkers.
Next-generation AR inhibitors Nubeqa and Erleada have shifted the treatment paradigm to include these therapies in earlier segments of disease such as non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). Expansion into earlier segments and lines of therapy is ongoing. Bayer is looking to expand Nubeqa's label to include use in very high-risk localized patients and metastatic hormone-sensitive patients. Johnson & Johnson will continue to try and differentiate Erleada with an aggressive development plan that includes potential expansions into chemotherapy-naive mCRPC patients as part of a combination with abiraterone, as well as into the localized setting for patients treated with prostatectomy or radiation therapy.
Akt inhibitors ipatasertib and capivasertib are a potential new mechanistic addition to the prostate cancer space, but the efficacy/tolerability profile of these PI3K/Akt/mTOR pathway inhibitors may prevent approval and potential usage. Ipatasertib is a pan-Akt inhibitor from Roche currently in development for asymptomatic or mildly symptomatic mCRPC patients with PTEN loss as part of a combination with abiraterone. PTEN loss is not a standard target in this indication, but represents a significant market opportunity as it is estimated to occur in approximately 20% of primary prostate cancers and up to 50% of castration-resistant tumors. However, ipatasertib is beset by known class toxicities of PI3K/Akt/mTOR pathway inhibitors such as diarrhea, rash, and ALT/AST elevations that could be detrimental to its regulatory chances. AstraZeneca's Akt inhibitor capivasertib has also demonstrated mixed results in prostate cancer.
In the Phase I/II ProCAID trial, capivasertib in combination with docetaxel failed to meet the primary endpoint of improved progression-free survival in mCRPC patients. However, the combination did improve overall survival in these patients irrespective of PI3K/Akt/mTOR pathway mutations. This has led to initiation of the Phase III CAPItello-281 trial testing capivasertib in combination with abiraterone in de novo mHSPC with PTEN loss.
Several checkpoint inhibitors are in development for prostate cancer, but late-phase data from ongoing combination trials are needed to fully determine their relative outlook in the indication. Merck is pursuing an aggressive late-phase development strategy for Keytruda in prostate cancer that includes combinations with Lynparza, Xtandi, and docetaxel for the treatment of mCRPC patients. Opdivo is also in late-phase development as part of a combination with docetaxel in mCRPC patients after failure on a next-generation hormone therapy. Finally, Roche's Tecentriq, the lone anti-PD-L1 antibody in late-phase development for prostate cancer, is currently in Phase III development in combination with Xtandi or in combination with Cabometyx in mCRPC patients after failing on a next-generation hormone therapy.
Myovant's relugolix is a GnRH receptor antagonist that is differentiated from available GnRH antagonist Firmagon by its oral formulation, which will facilitate use in patients undergoing localized definitive therapy who also need ADT and may also allow use of an intermittent ADT option in advanced hormone-sensitive patients looking to mitigate side effects and maintain quality of life.
Key Topics Covered:
OVERVIEW
DISEASE BACKGROUND
TREATMENT
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
KEY REGULATORY EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
DRUG ASSESSMENT MODEL
MARKET DYNAMICS
FUTURE TRENDS
CONSENSUS FORECASTS
RECENT EVENTS AND ANALYST OPINION
KEY UPCOMING EVENTS
KEY OPINION LEADER INSIGHTS
BIBLIOGRAPHY
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/jj2ao6
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Read the rest here:
Global Prostate Cancer Disease Coverage Forecast and Market Analysis 2020-2036 - Xtandi will Remain the Best-selling Therapy Over the Next Decade -...
- What Is a Hormone Doctor? | eHow [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Learn About Hormone Replacement Therapy [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Bioidentical Hormone Doctors, Thyroid Disorders, Lyme ... [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Natural Bioidentical Hormone Replacement Therapy (HRT ... [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- What Is a Hormone Doctor? | eHow StemCell Doctors [Last Updated On: June 4th, 2015] [Originally Added On: June 4th, 2015]
- Hormone Replacement Therapy in NYC | NYC Hormone ... [Last Updated On: June 24th, 2015] [Originally Added On: June 24th, 2015]
- Endocrinology - Wikipedia, the free encyclopedia [Last Updated On: September 21st, 2015] [Originally Added On: September 21st, 2015]
- AAG Health - Hormone Replacement Therapy | HGH & Testosterone [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
- Denver Bioidentical Hormone Therapy Clinic - Biovive Medicine [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
- Naturopathic Doctor Phoenix | Weight Loss Clinic ... [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
- What is an Endocrinologist? What does an Endocrinologist ... [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
- HRT | Hormone Replacement Therapy | Testosterone [Last Updated On: September 25th, 2015] [Originally Added On: September 25th, 2015]
- Endocrine disease - Wikipedia, the free encyclopedia [Last Updated On: September 29th, 2015] [Originally Added On: September 29th, 2015]
- Hormone Replacement Therapy - Ideal Physician Weight Loss [Last Updated On: October 21st, 2015] [Originally Added On: October 21st, 2015]
- Hormone Replacement | Fred Bloem, MD Holistic Physician ... [Last Updated On: October 24th, 2015] [Originally Added On: October 24th, 2015]
- How to Find a Bioidentical Hormone Doctor [Last Updated On: November 1st, 2015] [Originally Added On: November 1st, 2015]
- Neal Rouzier, MD The Hormone Doctor [Last Updated On: January 27th, 2016] [Originally Added On: January 27th, 2016]
- Hypothyroidism Diagnosis, Symptoms, and Treatment [Last Updated On: February 2nd, 2016] [Originally Added On: February 2nd, 2016]
- A Natural Progesterone Cream by Resonance Direct [Last Updated On: March 1st, 2016] [Originally Added On: March 1st, 2016]
- Network Of Doctors - Renew Man [Last Updated On: March 21st, 2016] [Originally Added On: March 21st, 2016]
- Dr. Komer, MD - Your Temporary Index [Last Updated On: March 25th, 2016] [Originally Added On: March 25th, 2016]
- Dr. Komer The Komer Clinics - Treatment, Education ... [Last Updated On: March 28th, 2016] [Originally Added On: March 28th, 2016]
- Atlantic Age Management - New Jersey Hormone Doctor ... [Last Updated On: April 3rd, 2016] [Originally Added On: April 3rd, 2016]
- Growth Hormone Treatment [Last Updated On: April 8th, 2016] [Originally Added On: April 8th, 2016]
- Information on Thyroid Disorders | Hormone Health Network [Last Updated On: May 11th, 2016] [Originally Added On: May 11th, 2016]
- Transgender hormone therapy Clinic [Last Updated On: June 8th, 2016] [Originally Added On: June 8th, 2016]
- DIM for Hormone Balance - Healthy by Nature [Last Updated On: June 30th, 2016] [Originally Added On: June 30th, 2016]
- MedHelp - Health community, health information, medical ... [Last Updated On: July 2nd, 2016] [Originally Added On: July 2nd, 2016]
- Hormone Replacement Therapy - WebMD [Last Updated On: July 23rd, 2016] [Originally Added On: July 23rd, 2016]
- Hormone Replacement Therapy Boca Raton - Hormone Doctor ... [Last Updated On: July 23rd, 2016] [Originally Added On: July 23rd, 2016]
- How to Balance Hormones Naturally | Wellness Mama [Last Updated On: July 24th, 2016] [Originally Added On: July 24th, 2016]
- Integrative Medicine Denver | Hormone Replacement Therapy [Last Updated On: August 28th, 2016] [Originally Added On: August 28th, 2016]
- HGH.com - Natural Human Growth Hormone Supplements [Last Updated On: September 5th, 2016] [Originally Added On: September 5th, 2016]
- The Physician Assistant Life - Essay [Last Updated On: September 24th, 2016] [Originally Added On: September 24th, 2016]
- Man vs. Estrogen: It's Not Just A Woman Thing! | Seasons ... [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- Bioidentical Hormones: Dr. John R. Lee's Three Rules for BHRT [Last Updated On: October 5th, 2016] [Originally Added On: October 5th, 2016]
- Endocrinology - Wikipedia [Last Updated On: October 25th, 2016] [Originally Added On: October 25th, 2016]
- TODAY Video - Latest TODAY show clips, news & video ... [Last Updated On: November 11th, 2016] [Originally Added On: November 11th, 2016]
- Hormonal Imbalance Anxiety a Precursor to Other Health ... [Last Updated On: December 7th, 2016] [Originally Added On: December 7th, 2016]
- DIM for Hormone Balance - blog.healthybynaturehwc.com [Last Updated On: December 7th, 2016] [Originally Added On: December 7th, 2016]
- Medicine - Wikipedia [Last Updated On: January 8th, 2017] [Originally Added On: January 8th, 2017]
- Steroid - Wikipedia [Last Updated On: January 8th, 2017] [Originally Added On: January 8th, 2017]
- Thyroid Disease Manager : Diagnosis and Treatment of Graves [Last Updated On: January 13th, 2017] [Originally Added On: January 13th, 2017]
- Dr. Brian Irwin: BPH is a common but uncomfortable disorder - Conway Daily Sun [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Hospital adds doctors at Dove's Landing - Oroville Mercury Register [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Veracyte (VCYT) Enters Agreement with Quest Diagnostics (DGX) to Expand Patient Access to GEC - StreetInsider.com [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Dear Dr. Roach: Elevated calcium level may signal excess hormone - Herald & Review [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Endocrine disease - Wikipedia [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- What causes infertility and how can it be treated? - WRDW-TV [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Doctor's Tip: What is the safest cookware? - Glenwood Springs Post Independent [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Nonbinary students confront surgery challenges - Yale Daily News (blog) [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Human Growth Hormone - Rejuvalife Vitality Institute [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Shed pounds to lower the risk - Times of India [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- Colorado House panel rejects three GOP abortion bills - The Denver Post [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- Dems defeat anti-choice bills - Pueblo Chieftain [Last Updated On: February 11th, 2017] [Originally Added On: February 11th, 2017]
- People get test results, have more tests done at Live Healthy 2017 Health Fair - Grand Island Independent [Last Updated On: February 12th, 2017] [Originally Added On: February 12th, 2017]
- Physicians' Education Resource Plans Most Impactful Miami ... - PR Web (press release) [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- Windsor doctor penalized for 'reckless' narcotics prescribing - Windsor Star [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- 'Bathroom Bill' is discrimination - Emporia Gazette [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- What's in store: Chronos - bestofneworleans.com [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- A lot of blood, for no reason? Common, costly clot test has few benefits - Knowridge Science Report [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Ask the Doctor: Dizziness, Graves' disease, herbal remedies - WNDU-TV [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- The Thyroid Problem: How you can identify thyroid issues and free your health - Black Hills Pioneer [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- 5 Reasons Real Women Chart Their Menstrual Cycle - Verily [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Holistic Medicine Doctor in Dever, Colorado | BioViveMD [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- With health care repeal looming, women turn to IUDs and other long-term birth control - Kansas City Star [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Older women reduce their endometrial cancer risk with weight loss - Fox News [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Chief justice cheers turnout at Longview off-site session - Longview News-Journal [Last Updated On: February 18th, 2017] [Originally Added On: February 18th, 2017]
- What's It Like Getting Health Care As A Black Transgender Person? - BuzzFeed News [Last Updated On: February 19th, 2017] [Originally Added On: February 19th, 2017]
- The Secret Behind Trump's Flowing Locks - eParisExtra.com (blog) [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- Family pushes bill expanding medical training in schools - WBIR.com [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- Quick fix: Zeman turns last-place Pescara around in 3 days - The Republic [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- Major study finds testosterone therapy is no fountain of youth - Philly.com [Last Updated On: February 21st, 2017] [Originally Added On: February 21st, 2017]
- Perth doctor Amish Dwarka Singh guilty over weight loss, bodybuilding prescriptions - ABC Online [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- Introducing Bio-Identical Hormone Replacement Therapy at Young Medical Spa in Center Valley and Lansdale ... - PR Web (press release) [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]
- Is testosterone-replacement therapy good or bad? One man suffering from low levels searches for answers. - Men's Fitness [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]
- Area doctor to launch book on women's health during menopause - Southgate News Herald [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]
- Obesity May Raise Girls' Risk of Asthma, Allergies - WebMD [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]
- Doc: Pill's hormone regulation benefits women with PCOS - The Detroit News [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]
- USMLE Step 1: Postpartum amenorrhea and hormone levels - American Medical Association (blog) [Last Updated On: March 6th, 2017] [Originally Added On: March 6th, 2017]